In this week's episode we’ll discuss the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies, learn how peak ADAMTS13 activity can be used to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura, and discuss the findings from a phase 2 trial of haploidentical bone marrow transplant in sickle cell disease.

Featured Articles

• Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies 
• Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated Thrombotic Thrombocytopenic Purpura 
• An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease